stockrowCRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.
- Revenue
- +1,325.1%
- EPS
- +1.55%
- Free cash flow
- −6.36%
Quarter to September 2026, against a year earlier
Follow CRSP
Alert me
CRISPR Therapeutics AG (CRSP) Free cash flow margin
CRISPR Therapeutics AG's free cash flow margin over the twelve months to 30 September 2026 was −1,496.6%, up 8358.9 percentage points from fiscal 2025 (−9,855.5%). Over the past ten years it has ranged from −44,484.9% (fiscal 2022) to 23,592.7% (fiscal 2015); the current reading is higher than 27% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | −9,855.5% | (9,467.78) |
| FY2024 | −387.7% | (315.03) |
| FY2023 | −72.7% | 44,412.20 |
| FY2022 | −44,484.9% | (44,534.87) |
| FY2021 | 50.0% | 35,755.68 |
| FY2020 | −35,705.7% | (35,722.96) |
| FY2019 | 17.3% | 3,186.66 |
| FY2018 | −3,169.4% | (2,979.37) |
| FY2017 | −190.0% | 939.44 |
| FY2016 | −1,129.5% | (24,722.18) |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| TVTX Travere Therapeutics, Inc. compare | 13.1% |
| COGT Cogent Biosciences, Inc. compare | 0.00% |
| MANE Veradermics Incorporated compare | 0.00% |
| ERAS Erasca, Inc. compare | 0.00% |
| DFTX Definium Therapeutics, Inc. compare | 0.00% |
| EWTX Edgewise Therapeutics, Inc. compare | 0.00% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −9.58% |
| CRSP CRISPR Therapeutics AG | −1,496.6% |
| DNTH Dianthus Therapeutics, Inc. compare | −6,469.9% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on CRSP
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement